Regeneron Pharmaceuticals stock
Price history
+37.48% over the period1 year: from $694.99 (November 13, 2025) to $955.47 (November 13, 2026), +37.48%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $955.47 |
| October 30, 2026 | $927.89 |
| September 30, 2026 | $758.27 |
| August 31, 2026 | $799.08 |
| July 31, 2026 | $762.63 |
| June 30, 2026 | $623.54 |
| May 29, 2026 | $614.78 |
| April 30, 2026 | $707.06 |
| March 31, 2026 | $772.64 |
| February 27, 2026 | $781.67 |
| January 30, 2026 | $741.45 |
| December 31, 2025 | $771.87 |
| November 28, 2025 | $780.19 |
| November 13, 2025 | $694.99 |
At a glance
The company
Develops medicines for eye, allergic, inflammatory, cardiovascular, metabolic, neurological, infectious and rare diseases and cancer
Latest results
Quarter to September 30, 2026 · EPS $20.07 (estimate $15.99)
Next event
Dividend
TickerLandia's take on Regeneron Pharmaceuticals
- Pricier than usual relative to earnings: P/E on the latest fiscal year 23 vs a median of 19 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 21 vs 35 (−39%) in a group of 7.
- Strong point: Market momentum (89/100 in its group). Weak point: Dividend (23/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−3.66% from the 52-week high
Analysts · 28 analysts
Average target$984.96+3.09% vs. price
Buy 19 · Hold 9 · Sell 0 · Buy
TickerLandia Fingerprint: Regeneron Pharmaceuticals
Compared with similar companies: very strong momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow24
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 13.5 14 P/E (trailing 12 months) 21.1 27 EV/EBITDA 15.8 30 Price/book 2.86 18 Price/sales 5.85 29 Profitabilityaverage57
How much it earns on revenue and capital.
Metric Value Position in group Net margin 28.5% 73 ROE 14.9% 60 Gross margin 46.7% 17 Operating margin 30.4% 71 ROA 7.6% 63 Earnings stabilityhigh73
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 12.3% 63 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthaverage51
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +5.62% 18 Revenue growth (year over year) +36.30% 68 Earnings growth (year over year) +35.50% 66 Financial strengthaverage57
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.03 43 Current ratio 3.35 52 Interest coverage 84.5 77 Debt/equitycounts in reverse: lower means more financial strength 0.08 58 Dividendlow23
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 2 years 46 Dividend yield 0.4% 14 Payout ratio 8.2% 8 Market momentumvery strong89
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +30.67% 87 Distance from 200-day average +27.92% 95 Relative strength (3 months) +22.27% 93 1-year return +37.48% 79 Riskaverage47
How much the price swings.
Metric Value Position in group Volatility (60 days) 39.5% 62 Beta (1 year) 0.38 35 Maximum drawdown (12 months) 26.1% 43
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Regeneron Pharmaceuticals is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Regeneron Pharmaceuticals's P/E today is 23.0, above the median of its last 10 fiscal years (18.7; between 8.77 and 47.7 from 2016 to 2025). Regeneron Pharmaceuticals's P/E (trailing 12 months): 21.1, −39% against the median of a group of 7 similar companies (34.7).
Compared with 7 similar companies
| Metric | Regeneron Pharmaceuticals | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 21.1 | Low | |
| Forward P/E | 13.5 | Low | |
| Operating margin | 30.4% | Middle | |
| ROE | 14.9% | Middle | |
| Debt/equity | 0.08 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Regeneron Pharmaceuticals. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$5.12B
Latest quarter · Q3 2026
Net income
$1.95B
Latest quarter · Q3 2026
Quarterly net margin
38.1%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $98.84B
- P/E
- 21.1
- EPS
- $45.24
- Volume
- 1.17M
- Daily trading
- €823.99M
- Dividend yield
- 0.39%
How Regeneron Pharmaceuticals is changing
All resultsRevenue grew 11.0% a year on average over the last 5 years
Operating margin fell from 38.9% to 24.9%
Profits turn into cash: free cash flow equal to 90% of net income
Returns
Regeneron Pharmaceuticals returns with dividends
$1,000 invested in Regeneron Pharmaceuticals 5 years ago, on November 15, 2021, would be worth $1,475 today: +47.51% in total, +8.10% per year. This is the price return only: dividends are excluded.
| Period | Regeneron Pharmaceuticals | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +26.87% | −3.12% | $1,269 |
| 6 months | +32.73% | +1.58% | $1,327 |
| Year to date | +23.79% | +10.46% | $1,238 |
| 1 year | +38.17% | +12.23% | $1,382 |
| 3 years | +19.93% | +71.41% | $1,199 |
| 5 years | +47.51% | +61.48% | $1,475 |
| 10 years | +114.94% | +249.40% | $2,149 |
Over the last 6 months it has done better than 70% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Regeneron Pharmaceuticals: technical analysis
Regeneron Pharmaceuticals is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 20.5% below its all-time closing high ($1,201.76, August 27, 2024).
- Trend
- Upward
- RSI (14 sessions)
- 68
- Between 30 and 70
- vs 200-session average
- +27.92%
Support and resistance
Price areas where Regeneron Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$955.47
- Support$853.17−10.71%2 touches, last on September 3, 2026
- Support$816.55−14.54%3 touches, last on September 23, 2026
- Support$792.84−17.02%3 touches, last on March 3, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.38
- Volatility (60 sessions, annualised)
- 39.5%
- Largest fall in the last year
- −26.05%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Regeneron Pharmaceuticals: seasonality
Average monthly price change over 36 years
Over the last 36 years, the strongest month for Regeneron Pharmaceuticals has been February: +8.66% on average, positive in 15 years out of 35. The weakest has been March: −4.33% on average, positive in 16 years out of 35. November, the current month, has been positive in 19 years out of 35 (+4.61% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.71% | +1.02% | 18 of 35 |
| February | +8.66% | −2.08% | 15 of 35 |
| March | −4.33% | −0.37% | 16 of 35 |
| April | +1.38% | −1.13% | 16 of 35 |
| May | +5.27% | +2.18% | 22 of 36 |
| June | +0.71% | −0.70% | 16 of 36 |
| July | +5.72% | +3.63% | 24 of 36 |
| August | +2.35% | +4.43% | 20 of 36 |
| September | +2.12% | −0.93% | 16 of 36 |
| October | +0.50% | −3.80% | 15 of 36 |
| November | +4.61% | +0.66% | 19 of 35 |
| December | +4.34% | −0.30% | 16 of 35 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Regeneron Pharmaceuticals and its competitors
Its product line begins with EYLEA injections, used for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinopathy of prematurity. The company also offers Dupixent for atopic dermatitis and asthma, Libtayo for metastatic or locally advanced cutaneous squamous cell carcinoma, Praluent for heterozygous familial hypercholesterolemia and Kevzara for rheumatoid arthritis.
- Headquarters
- Tarrytown, United States
- Employees
- 15,410
- Founded
- 1988
- Chief executive
- Leonard Schleifer
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Regeneron PharmaceuticalsREGN | $98.84B | 30.4% | 21.1 | +32.73% |
| ModernaMRNA | $90.38B | -80.8% | — | +343.02% |
| Vertex PharmaceuticalsVRTX | $136.56B | 37.8% | 34.7 | +18.88% |
| argenxARGX | $60.37B | 31.9% | 33.3 | +19.60% |
| BeOne MedicinesONC | $47.58B | 17.8% | 53.4 | +31.59% |
| Royalty PharmaRPRX | $39.85B | 64.4% | 45.3 | +30.16% |
Same industry or related industries, similar size. Compare Regeneron Pharmaceuticals with its competitors · Full profile
More on Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals revenue and financials
- Regeneron Pharmaceuticals dividend and valuation
- Regeneron Pharmaceuticals stock return
- Regeneron Pharmaceuticals employees, headquarters and business
